The impact of preoperative dexamethasone on the postoperative systemic inflammatory response and complications following surgery for colorectal cancer.

Authors

null

Stephen Thomas McSorley

University of Glasgow, Glasgow, United Kingdom

Stephen Thomas McSorley , Paul G. Horgan , Donald C McMillan

Organizations

University of Glasgow, Glasgow, United Kingdom

Research Funding

No funding sources reported

Background: It is now clear that there is a significant association between the magnitude of the systemic inflammatory response and postoperative complications (Adamina et al. Br J Surg 2015;102(6):590-8). The present study examined the impact of preoperative steroids on the postoperative systemic inflammatory response and complications, following elective surgery for colorectal cancer. Methods: The administration of dexamethasone at induction of anaesthesia was prospectively audited from a cohort of patients who underwent elective, potentially curative surgery for colorectal cancer at a single centre between 2008 and 2013. Results: 286 patients were included, of which the majority were male (161, 57%), over 65 (190, 66%) with colonic (183, 64%) and node negative disease (192, 67%). 114 (40%) received dexamethasone at induction of anaesthesia. There was a significant association (Table 1) between preoperative dexamethasone administration and the proportion of patients breaching established CRP thresholds on postoperative days 2 (190mg/L, 14% vs. 50%, p<0.001), and 3 (170mg/L, 27% vs. 49%, p<0.001) but not 4 (145mg/L, 50% vs. 36%, p=0.658). There was no significant association between preoperative dexamethasone and postoperative complications. Conclusions: The present study suggests that the systemic inflammatory response following surgery for colorectal cancer may be attenuated by preoperative steroids. It remains to be determined whether this will lead to a reduction in postoperative complications.

Outcomes following elective surgery for colorectal cancer.

OutcomeNo DexamethasonePreoperative DexamethasoneP
N172114-
POD 2 CRP (median,range,mg/L)191 (50-454)109 (16-317)<0.001
POD 2 CRP >190mg/L (yes/no)84/8416/95<0.001
POD 3 CRP (median,range,mg/L)169 (22-601)121 (17-430)<0.001
POD 3 CRP >170 mg/L (yes/no)81/8429/79<0.001
POD 4 CRP (median,range,mg/L)118 (13-528)119 (20415)0.180
POD 4 CRP >145 mg/L (yes/no)56/9930/600.658
Any complication (yes/no)70/10237/770.158
Infective complication (yes/no)45/12727/870.636
Anastomotic leak (yes/no)8/1643/1110.385

POD, postoperative day; CRP, C-reactive protein.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr 692)

DOI

10.1200/jco.2016.34.4_suppl.692

Abstract #

692

Poster Bd #

K11

Abstract Disclosures

Similar Abstracts

First Author: Stephen Thomas McSorley

First Author: Wenliang Li

First Author: Rebecca A Snyder

First Author: Li Jingjing